Skip to main content

Advertisement

SpringerLink
Log in

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Triple negative breast cancers (TNBC) are associated with an adverse outcome, although these tumors are sensitive to chemotherapy. In part, this phenomenon could be caused by tumor immune escape. The current study investigates immunogenicity of TNBC cells in vitro and the presence of immunosuppressive factors in the tumor microenvironment (pAKT and B7H1 expression, infiltration with regulatory T cells, [Tregs]).

Methods

Natural killer (NK)-cell induced lysis was evaluated in estrogen receptor (ER) positive MCF 7 breast cancers, in MDA-MB231 and MDA-MB468 and in HCC-1937 (BRCA 1 mutated) and HCC-1806 TNBC cells. Expression of pAKT, B7H1 and infiltration with Tregs were determined by immunohistochemistry in human specimens of benign and malignant breast disease.

Results

NK-cell induced lysis was significantly increased (p < 0.05) in four TNBC cell lines compared to ER + MCF 7 cells. Fibroadenomas and mastectomy samples were not infiltrated with Tregs. Infiltration with Tregs was 0.92 ± 0.21 in ER/PR + breast cancers and significantly higher in TNBC without (2.30 ± 0.34) and also significantly higher with mutation of BRCA 1 (2.10 ± 0.34). Expression of pAKT was absent in benign controls and 1.23 ± 0.36 in ER/PR + breast cancers, 1.78 ± 0.40 in TNBC without and 2.40 ± 0.30 with mutated BRCA 1. No significant differences of B7H1 expression occurred among the breast cancer subgroups.

Conclusion

TNBC cell stimulate the NK-cell immune response significantly stronger than ER positive breast cancer cells. This could explain why infiltration with immunosuppressive Tregs is increased in human specimens of TNBC with and without mutated BRCA 1. Accordingly, immunomodulatory treatment strategies should be further explored in TNBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A et al (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300

    Article  PubMed  Google Scholar 

  2. Prat A, Perou CM (2010) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5–23

    Article  PubMed  Google Scholar 

  3. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26(1):1–10

    Article  CAS  PubMed  Google Scholar 

  4. Alizadeh AA et al (2001) Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 195(1):41–52

    Article  CAS  PubMed  Google Scholar 

  5. Barrett SV (2010) Breast cancer. J R Coll Physicians Edinb 40(4):335–338 quiz 339

    Article  CAS  PubMed  Google Scholar 

  6. Schneider BP et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010–8018

    Article  CAS  PubMed  Google Scholar 

  7. Hennessy BT et al (2007) Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(24):7421–7431

    Article  CAS  PubMed  Google Scholar 

  8. Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434

    Article  PubMed  Google Scholar 

  9. Tanner B et al (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24(26):4317–4323

    Article  CAS  PubMed  Google Scholar 

  10. Rakha EA et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32

    Article  CAS  PubMed  Google Scholar 

  11. Haffty BG et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657

    Article  PubMed  Google Scholar 

  12. Nahleh Z (2010) Neoadjuvant chemotherapy for “triple negative” breast cancer: a review of current practice and future outlook. Med Oncol 27(2):531–539

    Article  CAS  PubMed  Google Scholar 

  13. Olkhanud PB et al (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69(14):5996–6004

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Tischkowitz M et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134

    Article  PubMed Central  PubMed  Google Scholar 

  15. Paradiso A, Formenti S (2011) Hereditary breast cancer: clinical features and risk reduction strategies. Ann Oncol 22(Suppl 1):i31–i36

    Article  PubMed  Google Scholar 

  16. Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7(12):702–707

    Article  CAS  PubMed  Google Scholar 

  17. Alfonso-De Matte MY et al (2002) Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res 62(16):4575–4578

    CAS  PubMed  Google Scholar 

  18. Darnell RB, Posner JB (2003) Observing the invisible: successful tumor immunity in humans. Nat Immunol 4(3):201

    Article  CAS  PubMed  Google Scholar 

  19. Wolf AM et al (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9(2):606–612

    PubMed  Google Scholar 

  20. Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2(5):373–382

    Article  CAS  PubMed  Google Scholar 

  21. Algarra I, Cabrera T, Garrido F (2000) The HLA crossroad in tumor immunology. Hum Immunol 61(1):65–73

    Article  CAS  PubMed  Google Scholar 

  22. Marincola FM et al (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273

    Article  CAS  PubMed  Google Scholar 

  23. Seliger B et al (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12(1):3–13

    Article  CAS  PubMed  Google Scholar 

  24. Kim R et al (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66(11):5527–5536

    Article  CAS  PubMed  Google Scholar 

  25. Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369–380

    Article  CAS  PubMed  Google Scholar 

  26. Kryczek I et al (2006) B7–H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4):871–881

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Kryczek I et al (2006) Cutting Edge: induction of B7–H4 on APCs through IL-10: novel suppressive mode for regulatory T Cells. J Immunol 177(1):40–44

    CAS  PubMed  Google Scholar 

  28. Curiel TJ et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949

    Article  CAS  PubMed  Google Scholar 

  29. Ling X et al (2010) Mesenchymal Stem Cells Overexpressing IFN-beta Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron 3(1):83–95

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Tan W et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548–553

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Black MM, Speer FD (1956) In vitro and clinical effects of urethane plus triethylene melamine on human breast cancer. Surg Gynecol Obstet 102(4):420–426

    CAS  PubMed  Google Scholar 

  32. Ladoire S et al (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125(1):65–72

    Article  CAS  PubMed  Google Scholar 

  33. Black MM, Opler SR, Speer FD (1956) Structural representations of tumor-host relationships in gastric carcinoma. Surg Gynecol Obstet 102(5):599–603

    CAS  PubMed  Google Scholar 

  34. Mahmoud SM et al (2011) An evaluation of the clinical significance of FOXP3 + infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99–108

    Article  CAS  PubMed  Google Scholar 

  35. Denkert C et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113

    Article  CAS  PubMed  Google Scholar 

  36. Ladoire S et al (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125(1):65–72

    Article  CAS  PubMed  Google Scholar 

  37. Yi T et al (2011) Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. J Immunol 186(5):2739–2749

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Wang S, Chen L (2011) Immunobiology of cancer therapies targeting CD137 and B7–H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol 344:245–267

    CAS  PubMed  Google Scholar 

  39. Parsa AT et al (2007) Loss of tumor suppressor PTEN function increases B7–H1 expression and immunoresistance in glioma. Nat Med 13(1):84–88

    Article  CAS  PubMed  Google Scholar 

  40. Hers I, Vincent EE, Tavare JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515–1527

    Article  CAS  PubMed  Google Scholar 

  41. Lopez-Knowles E et al (2010) PI3 K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126(5):1121–1131

    CAS  PubMed  Google Scholar 

  42. Lehmann BD et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Righi E et al (2011) CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71(16):5522–5534

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Regensburg, Caritas Krankenhaus St Josef, Landshuter Str 65, 93053, Regensburg, Germany

    Jörg B. Engel

  2. Universitätsfrauenklinik Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany

    Arnd Honig, Michaela Kapp, Jens C. Hahne, Susanne R. Meyer, Johannes Dietl & Sabine E. Segerer

Authors
  1. Jörg B. Engel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnd Honig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michaela Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jens C. Hahne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susanne R. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Johannes Dietl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabine E. Segerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg B. Engel.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 109 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Engel, J.B., Honig, A., Kapp, M. et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet 289, 141–147 (2014). https://doi.org/10.1007/s00404-013-2922-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2922-9

Keywords

Search

Navigation